Mylan has launched its generic version ... The launch environment for pharmaceutical industry products is evolving at pace with new scientific discoveries and shifting engagement patterns ...

A suit against Novartis and Vitaris by Henrietta Lacks’ estate hinges on questions about the morality and legality of using ...

"The product was approved last month and AMGN ... alleged that a biosimilar version of Eylea proposed by a Viatris's Mylan Pharmaceuticals unit infringes patents for the drug, used to treat ...

Pfizer and Mylan will continue to operate independent entities in Japan, but will collaborate on current and future generic products, sharing the costs and profits. The Japanese pharmaceutical ...

In a report released today, Balaji Prasad from Barclays maintained a Sell rating on Viatris (VTRS – Research Report), with a price target ...

Mylan President Rajiv Malik and Emcure Pharmaceuticals CEO Satish Mehta are both named ... among drugmakers to fix prices and allocate customers for at least 15 generic products. Connecticut Attorney ...

The Danish pharma company plans to launch Neffy in Europe in 2025 ... or medications. Injectable products, like Mylan’s ...

Viatris (VTRS) stock surges after Q3 earnings beat expectations with strong revenue growth and optimistic revenue outlook for ...

(CN) — Global pharmaceutical giant Sanofi-Aventis asked the 10th ... Sanofi claims that rather than offer a better product, Mylan offered extensive discounts to insurers for exclusively covering the ...

The European Commission (EC) has fined pharmaceutical company Teva € ... The patent office decision would allow Mylan ...

Pharmaceutical company Viatris (VTRS 13.52%) reported third-quarter 2024 financial results on Thursday, Nov. 7, that topped ...